Roche, Tadzio R.
Maas, Elise J. C.
Said, Sadiq
Braun, Julia
Machado, Carl
Spahn, Donat R.
Noethiger, Christoph B.
Tscholl, David W.
Article History
Received: 24 February 2022
Accepted: 20 May 2022
First Online: 30 May 2022
Declarations
:
: The study was conducted at University Hospital Zurich in Zurich, Switzerland in May 2020. Peter Kleist of the Cantonal Ethics Committee of the Canton of Zurich in Switzerland, reviewed the study protocol and issued a declaration of no objection (Business Management System for Ethics Committees Number Req-2020-00059). We obtained written informed consent from all participants. All methods were performed in accordance with the relevant guidelines and regulations.
: We obtained written informed consent from all participants for the use of their data for publication.
: DWT and CBN are designated inventors of Visual-Patient-avatar, for which the University of Zurich holds various patents and trademarks. There are cooperation and licensing agreements with Philips Medizin Systeme Böblingen GmbH, Böblingen, Germany; Koninklijke Philips NV, Amsterdam, The Netherlands; Philips Research/Philips Electronics Nederland BV, Eindhoven, The Netherlands; Philips USA, Cambridge, MA, USA. Under these agreements, DWT receives research funding, travel support, and DWT and CBN may receive royalties. DWT, CBN, and DRS are designated inventors of Visual Clot technology, for which the University of Zurich holds various patents and trademarks. The University of Zurich signed a letter of intent for cooperation and licensing agreement with Instrumentation Laboratory Company/Werfen Corporation, Bedford, MA, USA, and Barcelona, Spain. DWT, CBN, and DRS may receive royalties in the event of successful commercialization. DWT, CBN, and DRS received travel support for consulting Instrumentation Laboratory, Bedford, MA, USA. DWT received grant and travel support from the Swiss Foundation for Anesthesia Research, Zurich, Switzerland.CM is employee of Philips Research, Eindhoven, Netherlands. CM do not directly financially benefit from the success of the Visual patient technologies.DRS academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland, the Swiss Society of Anesthesiology and Perioperative Medicine (SSAPM), Berne, Switzerland, the Swiss Foundation for Anesthesia Research, Zurich, Switzerland, Vifor SA, Villars-sur-Glâne, Switzerland and Vifor (International) AG, St. Gallen, Switzerland.DRS is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany, LFB Biomédicaments, Courtaboeuf Cedex, France and Octapharma AG, Lachen, Switzerland.DRS received honoraria / travel support for consulting or lecturing from:Danube University of Krems, Austria, US Department of Defense, Washington, USA, European Society of Anesthesiology and Intensive Care, Brussels, BE, Korean Society for Patient Blood Management, Seoul, Korea, Korean Society of Anesthesiologists, Seoul, Korea, Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Paris, France, Alexion Pharmaceuticals Inc., Boston, MA, Bayer AG, Zürich, Switzerland, B. Braun Melsungen AG, Melsungen, Germany, CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland, Celgene International II Sàrl, Couvet, Switzerland, Daiichi Sankyo AG, Thalwil, Switzerland, Haemonetics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford, MA, USA, LFB Biomédicaments, Courtaboeuf Cedex, France, Merck Sharp & Dohme, Kenilworth, New Jersey, USA, Novo Nordisk Health Care AG, Zurich, Switzerland, PAION Deutschland GmbH, Aachen, Germany, Pharmacosmos A/S, Holbaek, Denmark, Pfizer AG, Zürich, Switzerland, Pierre Fabre Pharma, Alschwil, Switzerland, Portola Schweiz GmbH, Aarau, Switzerland, Roche Diagnostics International Ltd., Reinach, Switzerland, Sarstedt AG & Co., Sevelen, Switzerland and Nümbrecht, Germany, Shire Switzerland GmbH, Zug, Switzerland, Tem International GmbH, Munich, Germany, Vifor Pharma, Munich, Germany, Neuilly sur Seine, France and Villars-sur-Glâne, Switzerland, Vifor (International) AG, St. Gallen, Switzerland, Zuellig Pharma Holdings, Singapore, Singapore.The other authors do not have any conflicts of interest.